Answers are grounded in this paper and cite their sources.
The MBS landscape is undergoing a paradigm shift. Optimal obesity management is evolving beyond rigid anatomical algorithms towards precision medicine, driven by the synergistic integration of dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists, procedure personalisation based on metabolic phenotyping and robust lifelong surveillance registries tailored to regional demographics.
No takes yet. Share an insight, caveat, or question.
Dholakia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: